Prevalence of tobacco smoking and electronic cigarette use among adolescents in Italy: Global Youth Tobacco Surveys (GYTS), 2010, 2014, 2018.


Journal

Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116

Informations de publication

Date de publication:
02 2020
Historique:
received: 18 06 2019
revised: 13 09 2019
accepted: 11 11 2019
pubmed: 10 12 2019
medline: 27 1 2021
entrez: 9 12 2019
Statut: ppublish

Résumé

This research aims to study tobacco smoking and vaping among adolescents in Italy through three repeat national cross sectional surveys conducted before (in 2010, 2014) and after (2018) the 2016 introduction of the European Union - Tobacco Product Directive (EU-TPD) and its transposition into Italy, and before Juul entered the Italian market in 2019. Prevalence of smoking and vaping, access to cigarettes and electronic cigarettes in adolescents aged 13-15 years were estimated from the 2010, 2014, and 2018 Global Youth Tobacco Surveys (N = 1587; N = 1428; N = 1518, respectively) conducted in Italy. Prevalence of current smokers and/or current vapers combined, accounting for dual users, non-significantly increased from 20.7% in 2010 to 27.9% in 2018. Although current smokers stalled around 20%, current vapers substantially increased from 0% in 2010, 7.4% in 2014, to 17.5% in 2018, and current exclusive vapers recorded an almost 3-fold significantly increase from 2.9% in 2014 to 8.2% in 2018. Moreover, 42% of ever vapers used nicotine-free electronic cigarettes, and only 5% of current users were frequent vapers (≥20 days in the past month). About 65% of current smokers and 76% of current vapers easily accessed to cigarettes or electronic cigarettes in 2018. After 2 years from its implementation in 2016, the EU-TPD does not seem to have slowed down the increase in vaping among Italian adolescents before Juul entered the Italian market. Additional research is needed in order to show a clear association between EU-TPD and changes in vaping and smoking in Italy and in the EU.

Identifiants

pubmed: 31812559
pii: S0091-7435(19)30383-4
doi: 10.1016/j.ypmed.2019.105903
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105903

Investigateurs

Barbara Cortini (B)
Luisa Mastrobattista (L)
Claudia Mortali (C)
Rosilde Di Pirchio (R)
Gianluigi Ferrante (G)
Francesco Barone-Adesi (F)

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Giuseppe Gorini (G)

Occupational & Environmental Epidemiology Section, Oncologic Network, Prevention and Research Institute (ISPRO), Florence, Italy.

Silvano Gallus (S)

Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Giulia Carreras (G)

Occupational & Environmental Epidemiology Section, Oncologic Network, Prevention and Research Institute (ISPRO), Florence, Italy. Electronic address: g.carreras@ispro.toscana.it.

Barbara De Mei (B)

National Institute of Health (ISS), Rome, Italy.

Maria Masocco (M)

National Institute of Health (ISS), Rome, Italy.

Fabrizio Faggiano (F)

Oriental Piedmont University, Novara, Italy.

Lorena Charrier (L)

Department of Public Health and Paediatrics, University of Torino, Turin, Italy.

Franco Cavallo (F)

Department of Public Health and Paediatrics, University of Torino, Turin, Italy.

Lorenzo Spizzichino (L)

Italian Ministry of Health, Center for Disease Prevention and Control, Rome, Italy.

Daniela Galeone (D)

Italian Ministry of Health, Center for Disease Prevention and Control, Rome, Italy.

Valentina Minardi (V)

National Institute of Health (ISS), Rome, Italy.

Susanna Lana (S)

National Institute of Health (ISS), Rome, Italy.

Alessio Lachi (A)

Occupational & Environmental Epidemiology Section, Oncologic Network, Prevention and Research Institute (ISPRO), Florence, Italy.

Roberta Pacifici (R)

National Institute of Health (ISS), Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH